Mesenchymal Stem Cells Market Size & Share 2023 to 2032
Market Size by Type (Autologous, Allogeneic), Source (Adipose Tissue, Bone Marrow), Indication (Bone & Cartilage Repair, Cardiovascular Diseases), Application & Global Forecast.
Report ID: GMI6555
|
Published Date: August 2023
|
Report Format: PDF
Download Free PDF
Authors:
Mariam Faizullabhoy, Gauri Wani
Mesenchymal Stem Cells Market Size
Mesenchymal Stem Cells Market size accounted for USD 3 billion in 2022 and is estimated to grow at 12.8% to reach USD 10.3 billion by 2032 due to the rising prevalence of chronic diseases such as cancer, autoimmune disease, diabetes coupled with increasing implication in the field of immune therapy, drug discovery and regenerative medicine.
Mesenchymal Stem Cells Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
For instance, in 2019, according to the World Health Organization (WHO), 18 million people globally were suffering from rheumatoid arthritis. Thus, rising prevalence of autoimmune disease is significantly propelling the demand for mesenchymal stem cells to develop effective therapies. Furthermore, increasing R&D activities by biopharmaceutical companies and growing application of mesenchymal stem cells in toxicology and safety testing.
Mesenchymal stem cells (MSCs) are a type of multipotent stem cells that can differentiate into various cell types like bone, cartilage, and fat within the body's mesodermal lineage. These cells are found in various tissues of the body, such as bone marrow, adipose tissue, umbilical cord among others that possess self-renewal capabilities, enabling them to multiply and generate more MSCs. These cells offer distinctive feature and their ability to modulate the immune system, make them appealing for therapeutic applications in areas such as tissue repair, regenerative medicine, and immune modulation.
COVID-19 Impact
The emergence of the COVID-19 pandemic had significantly positive impact on the field of mesenchymal stem cells (MSCs) by directing attention toward their potential therapeutic applications. MSCs have shown promising results in managing COVID-19-related complications, particularly in addressing the severe inflammatory responses and lung damage associated with the virus. Early clinical trials and studies suggest that MSCs' immunomodulatory properties helps to mitigate the excessive immune response observed in severe cases of COVID-19, potentially reducing the severity of symptoms and improving patient outcomes. For instance, according to the ClinicalTrial.gov report, mesenchymal stem cells were investigated to determine the efficacy, effective and safe approach for the treatment of COVID-19 infection. This has led to increased research and investment in utilizing MSCs as a potential adjunct therapy for COVID-19 patients.
Mesenchymal Stem Cells Market Trends
Rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular ailments, and degenerative disorders have created significant demand for transformative therapies. Mesenchymal stem cells offers regenerative properties and immunomodulatory capabilities that position them as a promising candidates for treating chronic conditions by promoting tissue repair and modulating inflammatory responses. For instance, in 2020, according to the American Cancer Society, over 1.8 million new cancer cases were reported, and 606,520 people died of cancer in U.S. Similarly, in 2022, according to Parkinson’s Foundation, over 10 million people are suffering from Parkinson’s disease globally.
Mesenchymal Stem Cells Restraint
Lack of standardized protocols and comprehensive regulations acts as a notable barrier to the widespread adoption of mesenchymal stem cells that may potentially hamper the mesenchymal stem cells market. The absence of standardized procedures for MSC isolation, expansion, and administration can lead to variability in outcomes, making it difficult to ensure the safety and efficacy of treatments. Regulatory uncertainties and variations in approval processes across different regions further complicate the landscape, impeding the smooth progression of MSC therapies from research to clinical practice. Hence, lack of synchronisation not only impacts patient outcomes but also hampers the business environment, as biopharmaceutical companies face obstacles in navigating complex regulatory frameworks and ensuring the reproducibility of therapies.
Mesenchymal Stem Cells Market Analysis
By products & services, the mesenchymal stem cells market is classified into products and services. The products segment accounted for 76.8% of the market share in 2022. Mesenchymal stem cell products are further sub-segmented into kits, media, and reagents, cells & cell lines and other products. Kits and reagents are designed for mesenchymal stem cells research streamline experimental processes, ensuring accuracy and reproducibility. They provide optimized culture media & necessary components, reducing variability and expediting research timelines. Also, cells and cell lines offer consistent and reproducible material for studying stem cell behaviour, differentiation, and therapeutic potential.
By type, the mesenchymal stem cells market is classified into autologous and allogeneic. The allogeneic segment accounted for USD 1.8 billion market revenue in 2022. Allogeneic mesenchymal stem cells are sourced from compatible donors, providing a readily available supply for therapeutic applications without the necessity of obtaining cells from the patient's own tissues. This approach circumvents the time-consuming process of isolating autologous cells. Also, the scalability of allogeneic MSC production contributes to cost-effectiveness and broader accessibility. They can be thoroughly characterized and quality-controlled before use, ensuring consistent and reliable cell populations.
Based on source, the mesenchymal stem cells market is segmented into adipose tissue, bone marrow, cord blood, fetal liver, fallopian tube, lung, peripheral blood and other sources. The bone marrow segment is expected to register USD 2.6 billion by 2032. Increasing segmental progression is owing to relatively high concentration of mesenchymal stem cells in bone marrow as compared to other tissues. Also, mesenchymal stem cells derived from bone marrow exhibit robust proliferation capabilities that can be expanded in culture over multiple passages without losing their stem cell characteristics. Furthermore, robust regenerative potential and ability to differentiate into various cell types, mesenchymal stem cells derived from bone marrow hold promising potential in accelerating tissue repair, addressing degenerative disorders, and modulating immune responses.
By indication, the mesenchymal stem cells market is segmented into bone & cartilage repair, cardiovascular diseases, inflammatory and immunological diseases, liver diseases, cancer, graft versus host disease (GvHD) and other indications. The cardiovascular diseases segment is expected to grow at 11.8% by 2032. Mesenchymal stem cells offer significant regenerative potential in repairing damaged heart tissue, promoting angiogenesis, and enhancing cardiac function. These versatile stem cells offer distinct advantages in treating several conditions such as heart failure, myocardial infarction, vascular disorders among others. Also, their immunomodulatory properties further contribute to minimizing inflammation and immune responses that exacerbate cardiovascular damage.
The application in mesenchymal stem cells market is categorized into disease modeling, drug development & discovery, stem cell banking, tissue engineering, toxicology studies and other applications. Disease modeling segment accounted for USD 1.1 billion market revenue in 2022. Disease modeling involves replicating pathological conditions in a controlled environment to study disease mechanisms and potential treatments. Mesenchymal stem cells are well-suited for this purpose due to their versatility and immunomodulatory properties. They can be induced to differentiate into various cell types relevant to specific diseases, providing researchers with a platform to study disease progression and cellular interactions. Additionally, MSCs' immunomodulatory capabilities contribute to mimicking inflammatory responses seen in certain diseases. This enables researchers to observe cellular behaviour and test therapeutic interventions with greater accuracy.
North America mesenchymal stem cells market accounted for 42.4% market share in 2022. Increasing regional growth is owing to robust research infrastructure coupled with a strong emphasis on medical innovation, leading to a thriving environment for MSC-related advancements. Further, growing demand for effective disease diagnosis & therapies and favorable government regulations further support the expansion of mesenchymal stem cells.
Mesenchymal Stem Cells Market Share
Major market players operating in the mesenchymal stem cells market
Mesenchymal Stem Cells Industry News:
The mesenchymal stem cells market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Products & Services
By Type
By Source
Indication
Application
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →